Treatment of cachexia

An overview of recent developments

Stephan Von Haehling, Stefan D. Anker

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.

Original languageEnglish
Pages (from-to)726-742
Number of pages17
JournalInternational Journal of Cardiology
Volume184
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Cachexia
Ghrelin
Appetite Stimulants
Clinical Trials
Megestrol Acetate
Thalidomide
Survival
Nutritional Support
Carnitine
Melatonin
Interleukin-1
Testosterone
Chronic Disease
Anti-Inflammatory Agents
Monoclonal Antibodies
Quality of Life
Exercise
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cachexia
  • Cancer
  • Therapy
  • Wasting

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Treatment of cachexia : An overview of recent developments. / Von Haehling, Stephan; Anker, Stefan D.

In: International Journal of Cardiology, Vol. 184, No. 1, 2015, p. 726-742.

Research output: Contribution to journalArticle

Von Haehling, Stephan ; Anker, Stefan D. / Treatment of cachexia : An overview of recent developments. In: International Journal of Cardiology. 2015 ; Vol. 184, No. 1. pp. 726-742.
@article{d92def021c224bfaa8ca4877903aef70,
title = "Treatment of cachexia: An overview of recent developments",
abstract = "Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.",
keywords = "Cachexia, Cancer, Therapy, Wasting",
author = "{Von Haehling}, Stephan and Anker, {Stefan D.}",
year = "2015",
doi = "10.1016/j.ijcard.2014.10.026",
language = "English",
volume = "184",
pages = "726--742",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Treatment of cachexia

T2 - An overview of recent developments

AU - Von Haehling, Stephan

AU - Anker, Stefan D.

PY - 2015

Y1 - 2015

N2 - Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.

AB - Bodywasting in the context of chronic illness is associatedwith reduced quality of life and impaired survival. Recent clinical trials have investigated different approaches to improve patients' skeletalmusclemass and strength, exercise capacity, and survival in the context of cachexia and bodywasting,many of themin patientswith cancer. The aim of this article is to summarise clinical trials published over the last two years. Therapeutic approaches discussed here include appetite stimulants like megestrol acetate, L-carnitine, or melatonin, anti-inflammatory drugs like thalidomide, pentoxyphylline, or a monoclonal antibody against interleukin-1α as well as ghrelin and the ghrelin agonist anamorelin, nutritional support, and anabolics like enobosarm and testosterone.

KW - Cachexia

KW - Cancer

KW - Therapy

KW - Wasting

UR - http://www.scopus.com/inward/record.url?scp=84933523187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933523187&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.10.026

DO - 10.1016/j.ijcard.2014.10.026

M3 - Article

VL - 184

SP - 726

EP - 742

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -